SCHEMBL266841

SCHEMBL266841

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1cccc(F)c1)c1cccc(C(S)c2nc[nH]n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 1/20 0.45
SLC34A1 Q06495 1/20 0.45
SLC34A3 Q8N130 1/20 0.45
SLC20A1 Q8WUM9 1/20 0.45
KMT2A Q03164 4/20 0.39
GUSB P08236 2/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
POLB P06746 3/20 0.38
CTDSP1 Q9GZU7 2/20 0.38
PLEC Q15149 1/20 0.38
GPR35 Q9HC97 1/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
MAPT P10636 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268527 0.93 MAPT (0.46) SLC34A2SLC34A1SLC34A3SLC20A1KMT2A
SCHEMBL267565 0.91 SLC34A2 (0.55) SLC34A2SLC34A1SLC34A3SLC20A1KMT2A
SCHEMBL268412 0.91 RAB9A (0.47) KMT2AGUSBMEN1NPC1RAB9A
SCHEMBL266893 0.89 KMT2A (0.38) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL267064 0.89 RAB9A (0.43) KMT2AGUSBMEN1NPC1RAB9A
SCHEMBL266176 0.87 SLC34A2 (0.37) SLC34A2SLC34A1SLC34A3SLC20A1KMT2A
SCHEMBL265318 0.85 SLC34A2 (0.48) SLC34A2SLC34A1SLC34A3SLC20A1KMT2A
SCHEMBL266118 0.84 SLC34A2 (0.47) SLC34A2SLC34A1SLC34A3SLC20A1KMT2A
SCHEMBL269092 0.82 SLC34A2 (0.45) SLC34A2SLC34A1SLC34A3SLC20A1KMT2A
SCHEMBL269451 0.81 GUSB (0.41) KMT2AGUSBMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885SLC34A1 4/4885SLC34A3 12/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.